Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Breast Cancer
100%
Metastatic Breast Cancer
35%
Triple Negative Breast Cancer
34%
Overall Survival
29%
Hormone Receptor
26%
Gamma Urogastrone
22%
Progression Free Survival
21%
Neoadjuvant Chemotherapy
19%
Epidermal Growth Factor Receptor 2
18%
Palbociclib
17%
Capecitabine
15%
Neoplasm
15%
Hazard Ratio
15%
Clinical Feature
14%
Disease Free Survival
13%
Metastatic Carcinoma
12%
Hormone Therapy
11%
Malignant Neoplasm
11%
Estrogen Receptor
11%
Premenopause
11%
Radiation Therapy
10%
Alopecia Mucinosa
10%
Prognostic Factor
9%
Immune Checkpoint Inhibitor
9%
Survival Rate
9%
Letrozole
8%
Exemestane
8%
Adjuvant Therapy
8%
Gonadorelin Agonist
8%
Trastuzumab
7%
Circulating Tumor Cell
7%
Scalp
7%
Recurrent Disease
6%
Diseases
6%
Monotherapy
6%
Receptor Expression
5%
Gemcitabine
5%
Prevalence
5%
Biological Marker
5%
BRCA Mutation
5%
Survival Analysis
5%
Recurrence Free Survival
5%
Multivariate Analysis
5%
Immunotherapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
77%
Chemotherapy
47%
Metastatic Breast Cancer
38%
Gamma Urogastrone
30%
Epidermal Growth Factor Receptor 2
27%
Malignant Neoplasm
22%
Overall Survival
20%
Docetaxel
18%
Progression Free Survival
18%
Triple Negative Breast Cancer
17%
Hormone Receptor
16%
Neoplasm
14%
Trastuzumab
11%
Pertuzumab
10%
Eribulin
10%
Palbociclib
10%
Atezolizumab
10%
Clinical Trial
10%
Gemcitabine
9%
Letrozole
8%
Prevalence
8%
Capecitabine
8%
Biological Marker
8%
Disease Exacerbation
8%
Recurrent Disease
7%
Poziotinib
7%
Clinical Feature
7%
Paclitaxel
7%
First-Line Chemotherapy
7%
Prospective Cohort Study
7%
Phase II Trials
7%
Recurrence Free Survival
6%
Adverse Event
6%
Diseases
6%
Survival Rate
6%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
5%
Immunotherapy
5%
Neutropenia
5%
Biochemistry, Genetics and Molecular Biology
Genomics
28%
Overall Survival
28%
Epidermal Growth Factor Receptor
22%
Germ Cell
14%
Germline
14%
Progression Free Survival
14%
Disease Free Survival
13%
BRCA1
11%
Gemcitabine
10%
Clinical Trial
10%
Estrogen Receptor
10%
Prevalence
8%
Survival Rate
8%
Hormone Receptor
7%
Cytokine
7%
BRCA2
7%
RNA Sequencing
7%
Immune Checkpoints
7%
Vascular Endothelial Growth Factor A
7%
CXCL13
7%
Capecitabine
7%
Phase II Trials
7%
Recombination Repair
6%
Gene Expression
6%
Somatic Mutation
6%
Subtyping
6%
Exome Sequencing
6%
Gene Mutation
6%
Gene Expression Profiling
5%
Body Mass
5%
Cancer Registry
5%
Homologous Recombination
5%